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Angiogenesis, a key factor in ischemic heart disease, is rapidly initiated in response to hypoxic or
ischemic conditions. MicroRNAs (miRNAs) are endogenously expressed small non-coding RNAs that
regulate gene expression at post-transcriptional level. The recent discovery of the involvement of
these RNAs in the control of angiogenesis renders them very attractive in the development of
new approaches for restoring the angiogenic balance. In the present study, we explored that
miR-483-5p, a microRNA embedded in the intron of insulin-like growth factor 2 (Igf2), acts as an
endogenous angiogenesis-inhibiting factor. We identiﬁed that serum response factor (SRF) is one
of miR-483-5p target genes. These ﬁndings indicated that the miR-483-5p-SRF pathway may offer
a novel strategy for treatment with angiogenesis in ischemic heart disease patients.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction asa key factor in the angiogenesis process. They respond to indicatorsIschemic heart disease (IHD) causes myocardial injury when the
blood ﬂow to the myocardium is decreased or stopped by stenosis
or blockade. Recent advances in the understanding of the mecha-
nisms of neovascularization and the identiﬁcation of potent angio-
genic growth factors have led to the development of therapeutic
angiogenesis for treatment of severe ischemic heart disease [1].
Although therapeutic options such as reducing the risk factors, res-
toration of the blood ﬂow by angioplasty, or coronary bypass graft-
ing are applied broadly [2], these are insufﬁcient for treatment.
Angiogenesis is a key factor in the response to hypoxia or ischemic
conditions [3]. To develop new treatment methods for ischemic
heart disease, novel molecular mechanisms of angiogenesis need
to be discovered urgently.
Angiogenesis, the formationofnewbloodvessels frompreexisting
capillaries, is a sequence of events that is of key importance ina broad
array of physiologic and pathologic processes [4]. It has recentlybeen
reported that stimulation of angiogenesis might be a therapeutic
option for ischemic heart disease such as congestive heart failure
occurring after myocardial ischemia. Vascular endothelial cells actchemical Societies. Published by E
Jin), gaoxu_671227@yahoo.of balance between proangiogenesis and antiangiogenesis and help
maintain blood vessel homeostasis. Some studies have suggested
that insulin-like growth factor 2 (IGF2), transforming growth factor
b1 (TGF-b1), and IGF-1R [5] were involved in angiogenesis by
regulating the function of vascular endothelial cells.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate
many physiological and pathophysiological pathways [6,7]. Many
miRNAs have served as novel biomarkers, modulators, and espe-
cially therapeutic targets for disease. MiR-92a plays a role in angi-
ogenesis and functions in ischemic tissues [8]. MiR-126 is the only
miRNA known to be speciﬁcally expressed in the endothelial cell
lineage and hematopoietic progenitor cells; it promotes the func-
tion of vascular endothelial cells in angiogenesis [9]. Recently,
miR-483-5p, a conserved sequence encoded by intron 2 of igf2,
was identiﬁed [10]. The expression of this miRNA has been studied,
but there is no report on its function. Our previous study revealed
that miR-483-5p could be coexpressed with its host gene, igf2 [11].
Therefore, we hypothesized that miR-483-5p could play a biologi-
cal role as a functional partner of IGF2. Studies indicated that IGF2
promoted angiogenesis through the IGF2 receptor (IGF2R) system
in vascular endothelial cells [12], and alterations in the expression
of IGF2 were beneﬁcial for regulating cardiovascular functions
in vivo [13,14]. Regrettably, no study has investigated the expres-
sion and function of miR-483-5p in vascular endothelial cells.
In this study, miR-483-5pwas inhibited in human umbilical vein
endothelial cells (HUVECs) treated with the hypoxia-mimickinglsevier B.V. All rights reserved.
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ogenesis [16]. We tested the hypothesis that miR-483-5p regulates
angiogenesis in vitro. Tube formation and wound healing experi-
ments revealed that overexpression of miR-483-5p in endothelial
cells blocked angiogenesis, while inhibition of miR-483-5p in-
creased angiogenesis. MiR-483-5p appears to target the serum re-
sponse factor (SRF) by directly binding to its mRNA 30-UTR. Our
results showed that miR-483-5p regulated angiogenesis by target-
ing SRF. Thus, miR-483-5p may serve as a novel therapeutic target
for ischemic diseases.
2. Materials and methods
2.1. Cell culture reagents and hypoxia treatment
Human umbilical vein endothelial cells (HUVECs) were pur-
chased from ScienCell (Carlsbad, CA, USA) and cultured in endothe-
lial cell medium (ScienCell) supplemented with 5% fetal bovine
serum, endothelial cells growth supplement (ScienCell), and
100 lg/ml penicillin/streptomycin (ScienCell). Cells were incu-
bated in a temperature and humidity-controlled environmental
chamber SANYO (Japan) in an atmosphere containing 2% O2, 5%
CO2, 94% N2. Hypoxia was mimicked using 150 lM of the iron che-
lator deferoxamine (DFO) for 024 h, and for 24 h using 0150 lM
DFO obtained from Sigma (NY, USA).
2.2. Synthesis and transfection of miR-483-5p mimic and inhibitor
The miR-483-5p mimic oligonucleotide (based on 50-AAG ACG
GGA GAA GAG AAG GGA G-30 for mature human miR-483-5p),
the antisense inhibitor oligonucleotide (based on 50-ACT CCC TTC
TCT TCT CCC GTC TT-30), the negative control (NC) and the inhibitorFig. 1. Downregulation of miR-483-5p and upregulation of igf2 mRNA in HUVECs expos
treated with DFO, a hypoxia-mimicking compound. Real-time PCR analysis showed expre
treatment, 150 lM, 24 h) suppressed miR-483-5p expression in HUVECs. (C) igf2mRNA w
showed miR-483-5p and igf2 expression exposed to different concentrations of DFO fornegative control (IN NC) sequences were synthesized by Gene
Pharma Company (Shanghai, China). HUVECs were transfected
with miR-483-5p mimic, inhibitor, NC, and IN NC using X-treme-
GENE siRNA Transfection Reagent (Roche Diagnostics, IN, USA),
according to the manufacturer’s instructions. The ﬁnal concentra-
tion of miR-483-5p mimic and inhibitor used in these experiments
is 1 lg/ml.
2.3. Extraction of RNA and synthesis of cDNA
Total RNA containing the miRNA of HUVECs transfected with
miR-483-5p mimic, inhibitor, NC, or IN NC was isolated using TRI-
zol Regaent (Invitrogen, USA) according to the manufacturer’s
protocol. Afterwards, 1 lg of RNA from each sample was reverse
transcribed into complementary DNA (cDNA) using random primer
and subjected to conventional polymerase chain reaction (PCR).
2.4. Quantitative PCR for miR-483-5p
Total RNA was isolated as described above. Brieﬂy, 1 lg RNA
was transcribed into cDNA using an miR-483-5p-speciﬁc stem-
loop primer. Subsequent real-time PCR, using miR-483-5p-speciﬁc
primers synthesized by Shengong Company (Shanghai, China), was
performed on a 7500 Real Time PCR System (AB Applied Biosys-
tems, Mannheim, Germany).
2.5. Western blotting
Total protein from HUVECs transfected with miR-483-5p mi-
mic, inhibitor, NC or IN NC was extracted using RIPA buffer
(1 mM MgCl2, 10 mM Tris-HCl (pH 7.4), 1% Triton X-100, 0.1% so-
dium dodecyl sulfate (SDS), 1% NP-40), and protein expressioned to DFO. To evaluate the expression of miR-483-5p under hypoxia, HUVECs were
ssion of miR-483-5p, relative to U6 mRNA expression in HUVECs. (A) Hypoxia (DFO
as upregulated under hypoxia condition (DFO treatment, 150 lM, 24 h). (B) and (D)
24 h (⁄P < 0.05, n = 4 independent experiments).
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ogy, Santa Cruz, California, USA) served as a loading control. Total
protein extracts were separated on 12% SDS–polyacrylamide gel
electrophoresis (PAGE) gels and transferred to polyvinylidene ﬂuo-
ride (PVDF) membranes. The level of SRF or b-actin expression was
evaluated using the rabbit polyclonal anti-SRF or anti-b-actin anti-
body (Santa Cruz, California, USA), which is immunogen afﬁnity
puriﬁed. Bands were quantiﬁed with Image-Pro Plus software.
2.6. Scratch wound assay
Migration of HUVECs was detected using a scratch wound
assay. Brieﬂy, at 48 h after transfection, HUVECs transfected with
miR-483-5p mimic, inhibitor, NC, or IN NC were grown on 6-cm
dishes previously labeled with a traced line. The cell monolayer
was scraped with a sterile cell scraper to create a cell-free zone.
Thereafter, cells were washed with the medium and stimulated
as indicated. Endothelial cell migration was photographed at the
time of injury and after 24 and 48 h of cultivation, using an in-
verted microscope, at 5 distinct positions.
2.7. Tube formation assay
At 48 h after the transfection, HUVECs (7  104) were cultured
in a 12-well plate (Corning Star, NY, USA) coated with 200 ll
Matrigel Basement Membrane Matrix (BD Biosciences, USA). TubeFig. 2. Overexpression of miR-483-5p impaired angiogenesis in vitro. HUVECs were trans
migration, tubulogenesis and proliferation after 48 h. (A–C) Migration of transfected
measurements/condition; n = 4 independent experiments ⁄P < 0.05). (D,E) Transfected HU
for 24 h. Representative ﬁgures are shown in (D). Tube length (E) were quantiﬁed with Im
are means with the S.D. ⁄P < 0.05. (F) Proliferation was determined in transfected HUVElength was quantiﬁed after 24 h by measuring the cumulative tube
length in 5 random microscopic ﬁelds with an inverted
microscope.
2.8. MTT viability assay
Assessment of cell viability was performed using the MTT
[3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl-2H-tetrazolium bro-
mide] assay. 48 h after transfection, 0.5 mg/ml MTT was added to
each well and cells were incubated for 4 h at 37 C. Cells were
washedwith PBS and lysed 15 min at room temperaturewithDMSO
(Dimethyl Sulfoxide). MTT and DMSO were obtained from Sigma
(NY, USA). Absorbance was photometrically measured at 490 nm.
2.9. Luciferase activity assay
To generate the pMIR-SRF-30 UTR construct that contains the
putative binding site of the SRF 30 UTR downstream of the ﬁreﬂy
luciferase gene, a 395 bp sequence was cloned and inserted into
the SpeI and HindIII sites of the pMIR-REPORT Luciferase vector
(Ambion, Austin, TX, USA). For measuring luciferase activity,
HEK293 cells were grown in 24-well plates until 60–70% conﬂu-
ence. Next 100 ng Luciferase plasmid was cotransfected with
50 ng Renilla plasmid (Ambion, Austin, TX, USA) as a control for
transfection efﬁciency along with 650 ng miR-483 mimic or NC
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Thefected with a miR-483-5p mimic or with a mimic control (nc) and were assessed for
HUVECs in a scratch-wound assay 24 h and 48 h after transfection (n = 6–12
VECs were seeded onto matrigel and then allowed to form capillary-like structures
age J software (n = 5–10 pictures/condition; n = 4 independent experiments). Data
Cs by measuring MTT incorporation (⁄P < 0.05, n = 4 independent experiments).
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Dual Luciferase Reporter 1000 Assay System (Promega, Madison,
WI, USA).
2.10. Statistical analysis
The data are expressed as mean ± S.E.M. from at least three
independent experiments. The difference between two groups in
real-time PCR, tube formation assay, scratched wound assay, MTT
viability assay, and luciferase activity assay was analyzed using
the two-tailed Student’s t test. The difference was signiﬁcant to a
P value of <0.05.
3. Results
3.1. Downregulation of miR-483-5p and upregulation of igf2 in
HUVECs under hypoxia
To detect the expression of miR-483-5p in HUVECs under hy-
poxia condition, which induces angiogenesis, we used the iron che-
lator DFO, a hypoxia-mimicking compound [16]. The expression of
miR-483-5p was signiﬁcantly down regulated (Fig. 1A). However,
mRNA expression of the host gene, igf2, was upregulated in HU-
VECs under the same conditions (Fig. 1C). Expression of miR-
483-5p in HUVECs exposed to different concentrations of DFO for
24 h was also downregulated (Fig. 1B). Expression of igf2 inFig. 3. Inhibition of miR-483-5p promoted angiogenesis in vitro. HUVECs were transfecte
for migration, tubulogenesis and proliferation after 48 h. (A–C) Migration of transfect
measurements/condition; n = 4 independent experiments). D-E. Transfected HUVECs we
Representative ﬁgures are shown in (D). Tube length (E) were quantiﬁed with Image J soft
⁄P < 0.05. (F) Proliferation was determined in transfected HUVECs by measuring MTT inHUVECs exposed to different concentrations of DFO for 24 h was
upregulated (Fig. 1D).
3.2. MiR-483-5p regulated angiogenesis in vitro
To investigate the function of miR-483-5p in angiogenesis, ﬁrst,
we overexpressed miR-483-5p using miRNA mimic in HUVECs.
Then, we performed a scratch wound assay, tube formation, and
MTT viability assay. Overexpression of miR-483-5p inhibited
wound healing and vascular network formation (Fig. 2A-E). MiR-
483-5p inhibited the growth of HUVECs (Fig. 2F). To test its func-
tion further, we performed a scratch wound assay, tube formation
assay and MTT viability assay after transfection of miR-483-5p
inhibitors. Knockdown of miR-483-5p increased scratch wound as-
say, tube formation in matrigel assays and the growth of HUVECs
(Fig. 3). All of these results indicated that the downregulation of
miR-483-5p promotes angiogenesis in HUVECs.
3.3. MiR-483-5p reduced SRF expression in endothelial cells
SRF, a transcript factor required in angiogenesis, has been pre-
dicted as a potential target of miR-483-5p by the PicTar and micr-
oRNA.org target-prediction programs. To determine the effect of
miR-483-5p on SRF expression levels, total RNA and protein were
isolated from HUVECs cells that were transfected with miR-483-
5p mimic or NC, and miR-483-5p inhibitor or IN NC. The mRNAd with a miR-483-5p inhibitor or with a inhibitor control (in nc) and were assessed
ed HUVECs in a scratch-wound assay 24 h and 48 h after transfection (n = 6–12
re seeded onto matrigel and then allowed to form capillary-like structures for 24 h.
ware (n = 5–10 pictures/condition; n = 4 experiments). Data are means with the S.D.,
corporation (⁄P < 0.05, n = 4 independent experiments).
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criptase (RT)-PCR, and the protein level of SRF was detected by
western blotting. The results showed that the mRNA level of SRF
was trivially suppressed (Fig. 4A), and the protein level of SRF
was obviously suppressed (Fig. 4C–D) in HUVECs transfected with
the miR-483-5p mimic. Protein level of SRF in HUVECs transfected
with inhibitor was up-regulated. Expression of b-actin, which is
one of downstream genes of SRF, was reduced in HUVECs transfec-
ted with miR-483-5p and upregulated in HUVECs transfected with
inhibitor (Fig. 4C–E).
3.4. MiR-483-5p targeted the 30-UTR of SRF directly
To investigate the mechanism by which miR-483-5p regulated
angiogenesis, the direct target gene, SRF, was identiﬁed. MiR-
483-5p has been shown to function by directly binding to the 30-
UTR of its target gene SRF mRNA (Fig. 4B). We used a luciferase
experiment to identify that miR-483-5p suppressed the expression
of SRF by binding to its 30-UTR. When a 239-bp region of SRF 30-
UTR, containing 1 miR-483-5p-responsive element, was cloned
into a luciferase report vector, the luciferase activity decreased
by 45%, compared to that of the control (Fig. 4B).
4. Discussion
Regulating the function of vascular endothelial cells is a key
step in promoting angiogenesis and in the treatment of IHD. Stud-Fig. 4. MiR-483-5p reduces SRF expression in endothelial cells and targets SRF 30UTR di
SRF 30-UTR. Luciferase activity, normalized to Renilla activity, was measured in homogena
a miR-483-5p mimic or a scrambled control. Mutation of the target sequence resulted in
endogenous miR-483-5p. (C–E) MiR-483-5p reduced protein levels of SRF and b-actin. Inh
independent experiments).ies have suggested that many factors such as IGF2 and SRF [12–15]
are involved in angiogenesis. To further improve molecular ther-
apy, more research needs to be done on the mechanism underlying
this process.
MicroRNAs are a class of factors that control gene expression at
the post transcriptional level. Evidence indicates that microRNAs
are involved in controlling angiogenesis. Intronic miR-126 pro-
motes angiogenesis and indirectly regulates its host gene, Egﬂ7
[9]. Further, miR-92a [8] and miR-130a [17] control angiogenesis
by binding to the 30-UTR of target gene mRNAs that are critical
for angiogenesis. To date, only few miRNAs have been found to
be involved in angiogenesis regulation [18].
IGF2 is a growth factor that plays a role in fetal growth and tu-
mor development [19,20]. Studies have indicated that IGF2 could
regulate angiogenesis through the IGF2/IGF2R system, and miR-
483-5p was identiﬁed as an intronic miRNA encoded within intron
2 of igf2. Although, some expression proﬁles have revealed the
aberrant expression of miR-483-5p in tumors and fat [21,22], the
function of miR-483-5p remains unknown. Our previous study
showed that miR-483-5p could be coexpressed with its host gene
igf2. Therefore, we hypothesized that it plays a functional role with
IGF2.
To validate our hypothesis, we monitored the reduced expres-
sion of miR-483-5p upon the addition of angiogenic factors to
the culture medium. DFO, which mimics hypoxia inhibited miR-
483-5p expression. The decreased expression of miR-483-5p in
quiescent HUVECs suggests that miR-483-5p may be involved inrectly. (A) MiR-483-5p reduced SRF mRNA expression. (B) MiR-483-5p targeted the
tes of HEK cells transfected with the wild-type or mutated luciferase constructs and
a higher basal expression, indicating stabilization, possibly due to protection against
ibition of miR-483-5p upregulated protein levels of SRF and b-actin (⁄P < 0.05, n = 4
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the well-known angiogenic miRNA miR-126 followed a similar
pattern, highlighting the importance of miRNA in vascular homeo-
stasis control [26]. Investigation of miR-483-5p and miR-126
expression in proliferating versus quiescent blood vessels could
further our understanding the role of these miRNAs in vessel
homeostasis.
Interestingly, contrary to the upregulation of IGF2 mRNA under
hypoxic conditions (Fig. 1.C), miR-483-5p expression was down-
regulated by hypoxia. In our previous study, miR-483-5p was coex-
pressed with its host gene, igf2, in cancer cells. It is possible that
after DFO treatment of HUVECs, expression of miR-483-5p is no
longer synchronized with that of its host gene, suggesting a differ-
ent function of miR-483-5p in angiogenesis.
From the present study, miR-483-5p emerges as a new angio-
miR that negatively regulates angiogenesis. Using different
in vitro angiogenic assays, we demonstrated that miR-483-5p
overexpression and inhibition affect endothelial cell proliferation,
migration, and organization into tubes.
In order to elaborate a putative mechanism for miR-483-5p to
inhibit angiogenesis, we focused on the identiﬁcation of the targets
of this miRNA. Taken together, our results support a role for the
serum response factor v(SRF). SRF is an ancient and evolutionarily
conserved transcription factor of the MADS-box family that regu-
lates multiple genes implicated in cell growth, migration, cytoskel-
etal organization, energy metabolism and myogenesis [23]. SRF is
important for the correct expression of structural proteins such
as b-actin, VE-cadherin and several integrins in ECs, both in vitro
and in vivo, with changes in expression leading to the observed
defective vascular morphogenesis [24]. SRF mediates FGF signal-
ling in tracheal terminal branching, and VEGF/FGF signalling in
sprouting angiogenesis [25]. It will therefore be of great future
interest to study the inﬂuence of SRF in the expression of target
microRNAs in ECs during vascular development.
The SRF mRNA contains one putative conserved binding site for
miR-483-5p in the 30UTR, suggesting that SRF is a direct target of
miR-483-5p. The evolutionary conservation of this site suggests
that this target may be relevance. Our study supports the fact that,
in endothelial cells, miR-483-5p also represses SRF expression by
directly targeting its 30UTR (Fig. 4), and we also have found that
expression of b-actin, which is downstream of SRF in angiogenesis
[24,25], is reduced in HUVECs overexpressing miR-483-5p. How-
ever, additional target genes are likely to participate in the antian-
giogenic effects of miR-483-5p, and they remain to be investigated
in the future.
Ultimately, our ﬁndings suggest that manipulation of the miR-
483-SRF pathway may offer a novel strategy for increasing angio-
genesis in ischemic diseases and reveal a new phenomenon in
the functional relationship between intronic miRNA and host gene.
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